In an animal model of prostate cancer, coadministration of CCX771 (a CXCR7 inhibitor) and enzalutamide remarkably inhibited tumor growth and macrovascular formation, thus suppressing the drug resistance of enzalutamide.372. This evidence concerns the gene ACKR3 and prostate carcinoma.